<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990184</url>
  </required_header>
  <id_info>
    <org_study_id>1.2</org_study_id>
    <nct_id>NCT00990184</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)</brief_title>
  <official_title>A Single-Blind Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Institute for Biomedical and Clinical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Puget Sound Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Institute for Biomedical and Clinical Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the effect of 8 weeks of treatment with
      colesevelam HCl 3.75 g once daily with the evening meal on ß-cell function by evaluating the
      acute insulin response (AIRg) to an intravenous glucose load in subjects with prediabetes
      (impaired fasting glucose).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colesevelam is a bile acid sequestrant that was initially approved for treatment of patients
      with dyslipidemia. Subsequently it was observed that patients with type 2 diabetes receiving
      this medication had improved glucose control. However, the mechanism(s) by which it lowers
      glucose concentrations has not been determined.

      Glucose metabolism is enhanced following oral nutrient ingestion by the action of the
      incretin hormones. The two major incretin hormones are the peptides glucagon-like peptide-1
      (GLP-1) and glucose-dependent insulinotropic peptide (GIP), which are released from the
      intestinal tract wall in response to a meal. Of these two peptides, GLP-1 appears to be more
      important in regulating glucose metabolism. In the presence of elevated plasma glucose, GLP-1
      promotes insulin release from the ß-cells of the pancreas. GLP-1 also suppresses glucagon
      release, and thereby inhibits hepatic glucose output. Administration of GLP-1 by infusion or
      by subcutaneous injection has been shown to improve glucose tolerance in type 2 diabetic
      patients.

      The purpose of this study is therefore to determine in a cohort of individuals with
      prediabetes, who have an elevated fasting plasma glucose and are at increased risk of
      developing type 2 diabetes, whether the glucose lowering properties of colesevelam occur by
      it improving insulin sensitivity, islet ß-cell function or both. Further, by assessing the
      effect of colesevelam on incretin hormone release, it will be possible to determine whether
      any improvement in islet ß-cell function is due to enhanced incretin stimulation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Insulin Response (AIRg) to Intravenous Glucose</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Increase in insulin following glucose injection. AIRg is measured as the magnitude of the insulin response to an intravenous glucose injection calculated over the 10 minutes following glucose administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Tissue response to circulating insulin in the blood. Insulin sensitivity is measured using a mathematical model that quantifies the fractional rate of change in glucose concentrations per unit of insulin. Low values are insulin resistant and high values are insulin sensitive. *Please note: the &quot;-1&quot; in the Unit of Measure should be a superscripted value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Disappearance Rate</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Rate of fall of glucose in the blood</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Impaired Fasting Glucose</condition>
  <condition>Prediabetes</condition>
  <arm_group>
    <arm_group_label>Colesevelam Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam</intervention_name>
    <description>colesevelam HCl 3.75 g once daily orally with the evening meal</description>
    <arm_group_label>Colesevelam Hydrochloride</arm_group_label>
    <other_name>colesevelam HCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>tablet (s) orally given with evening meal</description>
    <arm_group_label>Colesevelam Hydrochloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females (postmenopausal, surgically sterile or using double-barrier method of
             contraception), aged 18-75 years, FPG 100-115 mg/dl at screening (average of 2
             measurements during screening; no individual measurement outside of the range 92-125
             mg/dl)

          -  In good health as determined by past medical history, physical examination,
             electrocardiogram, laboratory tests and urinalysis

          -  HbA1c &lt;6.5% at screening

          -  Body mass index (BMI) in the range of 22-40 kg/m2 inclusive and with a stable (+/-2.5
             kg) weight for the last 6 months

          -  Subjects must be willing to:

               -  Maintain prior exercise and dietary habits throughout the study

               -  Comply with all study requirements

               -  Provide written informed consent

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Patients diagnosed with type 2 diabetes or that have taken glucose-lowering agents or
             insulin, except during pregnancy

          -  Chronic oral or parenteral corticosteroid treatment (&gt;7 consecutive days of treatment)
             within 8 weeks prior to screening

          -  HIV protease inhibitors

          -  Warfarin or phenytoin use

          -  Triglycerides &gt;500 mg/dl

          -  History of major gastrointestinal tract surgery such as gastrectomy,
             gastroenterostomy, or bowel resection

          -  History of dysphagia, swallowing disorders or intestinal motility disorder

          -  History of pancreatitis

          -  Uncontrolled hypothyroidism

          -  Individuals with clinical hepatic disease or liver function tests greater than ≥2
             times upper limits of normal within 30 days preceding the first dose of study drug

          -  On a weight loss program with ongoing weight loss, or starting an intensive exercise
             program within 4 weeks of study initiation

          -  Current or prior (within the past 3 months) treatment with a bile acid sequestrant
             (colesevelam, colestipol, colestimide, or cholestyramine)

          -  Use of any investigational drug in the last 30 days

          -  Donation of one unit (500 ml) or more of blood, significant blood loss equaling at
             least one unit of blood within the past 2 weeks or a blood transfusion within 8 weeks
             prior to screening

          -  Employment by the research center
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven E Kahn, MB CHB</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Puget Sound Healthcare System</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2009</study_first_submitted>
  <study_first_submitted_qc>October 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2009</study_first_posted>
  <results_first_submitted>February 1, 2012</results_first_submitted>
  <results_first_submitted_qc>October 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 21, 2012</results_first_posted>
  <last_update_submitted>October 22, 2012</last_update_submitted>
  <last_update_submitted_qc>October 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Impaired Fasting Glucose</keyword>
  <keyword>PreDiabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Colesevelam Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Colesevelam Hydrochloride</title>
          <description>People with IGT will take 2 weeks of placebo and then 8 weeks of study drug</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Colesevelam Hydrochloride</title>
          <description>People with IGT will take 2 weeks of placebo and then 8 weeks of study drug</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.7" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acute Insulin Response (AIRg) to Intravenous Glucose</title>
        <description>Increase in insulin following glucose injection. AIRg is measured as the magnitude of the insulin response to an intravenous glucose injection calculated over the 10 minutes following glucose administration.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Subjects who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>Effect of colesevelam treatment compared to baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Insulin Response (AIRg) to Intravenous Glucose</title>
          <description>Increase in insulin following glucose injection. AIRg is measured as the magnitude of the insulin response to an intravenous glucose injection calculated over the 10 minutes following glucose administration.</description>
          <population>Subjects who completed the study</population>
          <units>pmol/1*min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1866" lower_limit="678" upper_limit="2670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1752" lower_limit="564" upper_limit="3306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Sensitivity</title>
        <description>Tissue response to circulating insulin in the blood. Insulin sensitivity is measured using a mathematical model that quantifies the fractional rate of change in glucose concentrations per unit of insulin. Low values are insulin resistant and high values are insulin sensitive. *Please note: the &quot;-1&quot; in the Unit of Measure should be a superscripted value.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam 3.75 g Daily</title>
            <description>Medication used to treat people with increased cholesterol levels</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity</title>
          <description>Tissue response to circulating insulin in the blood. Insulin sensitivity is measured using a mathematical model that quantifies the fractional rate of change in glucose concentrations per unit of insulin. Low values are insulin resistant and high values are insulin sensitive. *Please note: the &quot;-1&quot; in the Unit of Measure should be a superscripted value.</description>
          <units>min-1 per pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Disappearance Rate</title>
        <description>Rate of fall of glucose in the blood</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>Effect of colesevelam treatment compared to baseline (end of two week placebo run in period)</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Disappearance Rate</title>
          <description>Rate of fall of glucose in the blood</description>
          <units>percentage of glucose/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Colesevelam Hydrochloride</title>
          <description>People with IGT will take 2 weeks of placebo and then 8 weeks of study drug</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>TIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven E. Kahn</name_or_title>
      <organization>SIBCR</organization>
      <phone>206-277-5515</phone>
      <email>skahn@u.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

